Genfit (NASDAQ:GNFT) Stock Price Down 0.2%

Genfit S.A. (NASDAQ:GNFT)’s stock price was down 0.2% during trading on Monday . The stock traded as low as $4.15 and last traded at $4.26. Approximately 8,318 shares traded hands during trading, a decline of 53% from the average daily volume of 17,548 shares. The stock had previously closed at $4.27.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Genfit in a research report on Monday, July 29th.

Genfit Price Performance

The company has a current ratio of 2.94, a quick ratio of 2.94 and a debt-to-equity ratio of 0.92. The firm has a fifty day simple moving average of $4.18 and a two-hundred day simple moving average of $3.97.

Institutional Investors Weigh In On Genfit

An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. increased its position in shares of Genfit S.A. (NASDAQ:GNFT) by 2,229.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 82,359 shares of the company’s stock after acquiring an additional 78,823 shares during the period. Optiver Holding B.V. owned approximately 0.17% of Genfit worth $315,000 as of its most recent filing with the Securities and Exchange Commission. 2.24% of the stock is owned by institutional investors and hedge funds.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.